论文部分内容阅读
目的:观察伊曲康唑治疗重症监护室(ICU)患者侵袭性真菌感染的临床疗效和安全性。方法:回顾性分析2009年1月～2009年9月入住上海交通大学医学院附属新华医院急诊ICU的21例侵袭性真菌感染患者,经伊曲康唑治疗的疗效及安全性。结果:总临床治愈率为52.3%;培养所得的103例菌株均进行药物敏感性试验,结果显示均对伊曲康唑敏感,其总细菌清除率为57.1%;确诊及临床诊断病例、拟诊病例的临床治愈率分别为33.3%、56.2%、50.0%,细菌清除率分别为33.3%、62.5%、50.0%。药品不良反应总发生率为14.2%。结论:伊曲康唑治疗重症监护患者侵袭性真菌感染安全有效,但心功能不全患者应慎用,使用过程中需监测生命体征、病情变化。
Objective: To observe the clinical efficacy and safety of itraconazole in the treatment of invasive fungal infections in intensive care unit (ICU) patients. Methods: The efficacy and safety of itraconazole in 21 patients with invasive fungal infection admitted to Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine from January 2009 to September 2009 were retrospectively analyzed. Results: The total clinical cure rate was 52.3%. All the 103 strains were tested for drug susceptibility. The results showed that all of them were sensitive to itraconazole, with a total bacterial clearance rate of 57.1%. The diagnosed and clinically diagnosed cases were diagnosed The clinical cure rates were 33.3%, 56.2% and 50.0% respectively, and the bacterial clearance rates were 33.3%, 62.5% and 50.0% respectively. The total incidence of adverse drug reactions was 14.2%. CONCLUSION: Itraconazole is safe and effective for the treatment of invasive fungal infections in intensive care patients. However, patients with cardiac insufficiency should be cautiously used and vital signs and changes of the disease should be monitored during use.